Listed by the USPTO as BRETZ, COREY LANE
Tech Center 1600 • Art Units: 1600 1633 1635 1656 1658
This examiner grants 0% of resolved cases
BRETZ, COREY LANE works in Tech Center 1600 and art unit 1600. The record contains 3 resolved cases, with an allowance rate of 0.0%. The median time to allowance is 954 days, and the interview lift is 0.0%.
The listed companies are GENZYME Corporation, President and Fellows of Harvard College, and Salk Institute for Biological Studies. The listed firms are BANNER & WITCOFF, LTD., KLARQUIST SPARKMAN, LLP, and Lathrop GPM LLP | Sanofi-Aventis. The limited record offers little basis for general prediction, and it shows no allowance or interview-associated change. Practitioners should rely on the specific application record.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18338150 | COMPOSITIONS AND METHODS FOR MODIFYING RNA | Final Rejection | The Regents of the University of California |
| 18283262 | PRODUCTION OF CIRCULAR POLYRIBONUCLEOTIDES IN A PROKARYOTIC SYSTEM | Non-Final OA | FLAGSHIP PIONEERING INNOVATIONS VII, LLC |
| 18901470 | Methods for Rule-based Genome Design | Non-Final OA | President and Fellows of Harvard College |
| 17719431 | Methods for Rule-based Genome Design | Non-Final OA | President and Fellows of Harvard College |
| 18291018 | GENERATION OF LARGE PROTEINS BY CO-DELIVERY OF MULTIPLE VECTORS | Non-Final OA | UNIVERSITY OF WASHINGTON |
| 17773572 | ENGINEERED CELLS FOR CONTROLLED PRODUCTION | Non-Final OA | William Marsh Rice University |
| 17921338 | TARGETED GENOMIC INTEGRATION TO RESTORE NEUROFIBROMIN CODING SEQUENCE IN NEUROFIBROMATOSIS TYPE 1 (NF1) | Final Rejection | Duke University |
| 18151093 | RECOMBINANT ADENOVIRUS GENOME HAVING A SYNTHETIC TRANSCRIPTIONAL UNIT AND TWO STEP TRANSCRIPTIONAL REGULATION AND AMPLIFICATION | Non-Final OA | Salk Institute for Biological Studies |
| 17741311 | COMPOSITIONS AND METHODS FOR HIGH-EFFICIENCY RECOMBINATION OF RNA MOLECULES | Non-Final OA | Salk Institute for Biological Studies |
| 18483090 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR USING HLA-F | Non-Final OA | THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 18687892 | IVT RNA MANUFACTURING PROCESS | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy0.0% of resolved applications examined by Corey Lane Bretz were allowed (3 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +0.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Corey Lane Bretz took 954 days on average from filing to allowance.
Corey Lane Bretz examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
